• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Peraza Lisa claimed ownership of 45,189 units of Ordinary Shares (SEC Form 3)

    3/16/26 4:46:04 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CNTB alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Peraza Lisa

    (Last) (First) (Middle)
    3580 CARMEL MOUNTAIN ROAD, SUITE 200

    (Street)
    SAN DIEGO CA 92130

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/16/2026
    3. Issuer Name and Ticker or Trading Symbol
    Connect Biopharma Holdings Ltd [ CNTB ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Senior Vice President, Finance
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Ordinary Shares 45,189 D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Employee Stock Option (Right to Buy) (1) 08/12/2034 Ordinary Shares 400,000 $1.15 D
    Employee Stock Option (Right to Buy) (1) 12/26/2034 Ordinary Shares 55,318 $0.97 D
    Employee Stock Option (Right to Buy) (1) 07/07/2035 Ordinary Shares 40,000 $1.14 D
    Employee Stock Option (Right to Buy) (2) 12/26/2035 Ordinary Shares 250,000 $2.69 D
    Explanation of Responses:
    1. The stock option vests and becomes exercisable over four years, with 25% vesting on the first anniversary of the date of grant, and then with respect to the remaining shares on a ratable monthly basis over the next three years, subject to continuous service with the Company as of each applicable vesting date.
    2. The stock option vests and becomes exercisable on a ratable monthly basis over four years, subject to continuous service with the Company as of each applicable vesting date.
    Remarks:
    /s/ Lisa Peraza 03/16/2026
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CNTB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CNTB

    DatePrice TargetRatingAnalyst
    12/1/2025$9.00Buy
    Lake Street
    10/31/2025$10.00Buy
    BTIG Research
    6/12/2025$7.00Buy
    H.C. Wainwright
    3/4/2024$7.00Buy
    H.C. Wainwright
    More analyst ratings

    $CNTB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

    – Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or COPD – – Results from Phase 3 study of rademikibart in moderate-to-severe AD presented in late-breaking research session at AAD – – Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies mid-2026 – – Entered into a securities purchase agreement for $20.2 million equity financing extending our cash runway into second half of 2027 – SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceuti

    3/31/26 4:05:00 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connect Biopharma Announces $20.2 Million Private Placement Financing

    Funding from new and existing investors extends anticipated cash runway into the second half of 2027 SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma," "Connect" or the "Company"), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell 6,130,000 shares of its ordinary shares in a private placement at a price of $3.25 per share with respect to any purchaser that is not owned or controlled by an individual who is an officer, dir

    3/30/26 7:02:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study

    – Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near‑maximal responses achieved in ~90% of patients – – Rademikibart was well tolerated with safety comparable to placebo – – Data presented during late-breaking oral presentation at 2026 American Academy of Dermatology Annual Meeting –  – Company to host conference call and webcast today, March 30, 2026 at 8:00 a.m. ET – SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today anno

    3/30/26 7:01:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTB
    SEC Filings

    View All

    SEC Form 10-K filed by Connect Biopharma Holdings Limited

    10-K - Connect Biopharma Holdings Ltd (0001835268) (Filer)

    3/31/26 4:10:38 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connect Biopharma Holdings Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Connect Biopharma Holdings Ltd (0001835268) (Filer)

    3/31/26 4:07:41 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connect Biopharma Holdings Limited filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Connect Biopharma Holdings Ltd (0001835268) (Filer)

    3/30/26 7:06:04 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Xanthopoulos Kleanthis Gabriel

    4 - Connect Biopharma Holdings Ltd (0001835268) (Issuer)

    4/2/26 4:27:54 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Liu Jean I

    4 - Connect Biopharma Holdings Ltd (0001835268) (Issuer)

    4/2/26 4:25:01 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Huang James

    4 - Connect Biopharma Holdings Ltd (0001835268) (Issuer)

    4/1/26 4:30:16 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Connect Biopharma with a new price target

    Lake Street initiated coverage of Connect Biopharma with a rating of Buy and set a new price target of $9.00

    12/1/25 9:37:24 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Connect Biopharma with a new price target

    BTIG Research initiated coverage of Connect Biopharma with a rating of Buy and set a new price target of $10.00

    10/31/25 8:19:20 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Connect Biopharma with a new price target

    H.C. Wainwright initiated coverage of Connect Biopharma with a rating of Buy and set a new price target of $7.00

    6/12/25 7:54:22 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTB
    Financials

    Live finance-specific insights

    View All

    Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study

    – Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near‑maximal responses achieved in ~90% of patients – – Rademikibart was well tolerated with safety comparable to placebo – – Data presented during late-breaking oral presentation at 2026 American Academy of Dermatology Annual Meeting –  – Company to host conference call and webcast today, March 30, 2026 at 8:00 a.m. ET – SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today anno

    3/30/26 7:01:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD

    – Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pulmonary disease (COPD) patients produced rapid improvement in FEV1 with many patients experiencing improvements in airway function of ≥200 mL as early as 15 minutes post-dosing – – The rapid improvement in FEV1 demonstrated with IV rademikibart in this study provides clinical confirmation of preclinical observations that rademikibart has a unique beneficial effect on bronchodilation – – Mean FEV1 improvements of ~200 - 400 mL were maintained through Day 29 in asthma and COPD patients – – Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD;

    3/30/26 7:00:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma

    The global trial met its primary endpoint showing both doses of rademikibart treatment significantly improved lung function at Week 12The significant improvement in lung function was observed as early as Week 1 and was sustained through Week 24 with both doses of rademikibartSignificant improvement in asthma control occurred early and was sustained through Week 24 for both doses of rademikibartSafety results suggest rademikibart was generally well toleratedA conference call and webcast presentation to discuss the data will be held today at 8:30 a.m. ET, details below SAN DIEGO, CA and TAICANG, China, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:

    12/12/23 6:00:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Connect Biopharma Holdings Limited

    SC 13D/A - Connect Biopharma Holdings Ltd (0001835268) (Subject)

    7/1/24 4:16:48 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Connect Biopharma Holdings Limited (Amendment)

    SC 13D/A - Connect Biopharma Holdings Ltd (0001835268) (Subject)

    2/27/24 9:00:28 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Connect Biopharma Holdings Limited (Amendment)

    SC 13D/A - Connect Biopharma Holdings Ltd (0001835268) (Subject)

    2/27/24 4:19:26 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTB
    Leadership Updates

    Live Leadership Updates

    View All

    Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors

    – Mr. Schoeneck is a seasoned industry executive and director with deep expertise in development and commercialization of breakthrough products and guiding companies through significant transformation and growth – SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced the expansion of the size of its Board of Directors from six to seven directors and the appointment of Jim Schoeneck as a director effective today. "We are pleased to welcome Jim to our Board of Directors," sai

    7/22/25 9:00:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Attovia Therapeutics Appoints Chief Financial Officer

    FREMONT, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics announced the appointment of Steven Chan as Chief Financial Officer. Mr. Chan brings extensive financial strategy and operational experience and joins Attovia after serving as Chief Financial Officer at Connect Biopharma (NASDAQ:CNTB), a global clinical-stage biopharmaceutical company focused on T cell-driven therapeutics for inflammatory diseases. At Attovia, Mr. Chan will lead the company's finance and operations functions and serve on its Executive Committee, reporting to Tao Fu, Chief Executive Officer. "I am delighted to welcome Steve to Attovia at this critical growth period for the company. He brings over thirt

    10/15/24 7:30:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update

    Announced new U.S.-based leadership with the appointment of Barry Quart, Pharm.D. as Chief Executive Officer (CEO) and David Szekeres as PresidentConnect's new management is currently evaluating the future clinical development strategy for rademikibartAs part of Connect's transformation into a U.S.-centric company, the Company will be significantly reducing its presence in ChinaCash and cash equivalents of $110.2 million expected to support planned operations into at least the first half of 2027 SAN DIEGO, CA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma," "Connect" or the "Company"), a U.S.-headquartered global clinical-stage bio

    9/5/24 4:05:00 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care